AstraZeneca-BMS Take Over Byetta Sales In China, Kick Off Expanded Diabetes Lineup
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca and Bristol-Myers Squibb took over Byetta sales and marketing rights in China from Eli Lilly this month, marking a ramp-up in offerings for the world’s largest diabetes population.